Dosage regime
AssigneeNovabiotics Limited
InventorDeborah O'Neil
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to use of cysteamine, formulations comprising cysteamine and pharmaceutically acceptable salts of cysteamine in the treatment of cystic fibrosis and conditions associated with cystic fibrosis.
Claims11
A method of treating pulmonary exacerbations in cystic fibrosis, the method comprising administering to a patient in need thereof, cysteamine, or a pharmaceutically acceptable salt thereof, bi-daily as two sub-doses to form a total daily dose, wherein each sub-dose is in a range of 400 to 600 mg and the bidaily sub-doses are administered 8-12 hours apart, wherein the patient in need thereof exhibits pulmonary exacerbations in cystic fibrosis and wherein the treating relates to imparting a benefit to patients afflicted with cystic fibrosis or a condition associated with cystic fibrosis.
Dependencies are inferred from the claim text.